Dendrimer functionalized folate-targeted gold nanoparticles for luciferase gene silencing in vitro: A proof of principle study-Reference-Cited by-同舟云学术

Dendrimer functionalized folate-targeted gold nanoparticles for luciferase gene silencing in vitro: A proof of principle study

Published:2018-12-07 Issue:1 Volume:69 Page:49-61
ISSN:1846-9558
Container-title:Acta Pharmaceutica
language:en
Short-container-title:

Author:

Mbatha Londiwe Simphiwe¹,Maiyo Fiona Chepkoech¹,Singh Moganavelli¹

Affiliation:

1. Non-Viral Delivery Laboratory Discipline of Biochemistry University of KwaZulu-Natal Westville Campus, School of Life Sciences , Private Bag X54001, Durban 4000 South Africa

Abstract

Abstract Use of exogenous small interfering RNA (siRNA) has shown potential in gene silencing. The need for target-specific siRNA delivery vehicles is crucial to successful gene silencing. This study is aimed at developing and evaluating the safety and efficiency of siRNA delivery using unmodified and folic acid (FA) modified poly(amidoamine) generation 5 (PAMAM G5D) functionalized gold nanoparticles (Au:G5D/Au:G5D:FA) in vitro. All formulations were physico--chemically characterized and nanocomplexes were evaluated using the band shift, dye displacement, nuclease protection, MTT cell viability, and luciferase reporter gene assays. Nanocomplexes bound and protected siRNA against degrading RNases, and were well tolerated by the cells. The Au:G5D:FA nanocomplexes elicited excellent gene silencing in folate receptor expressing HeLa-Tat-Luc cells, decreasing significantly in the presence of excess FA ligand, indicating nanocomplex uptake by the mechanism of receptor mediation. These results highlight the synergistic role played by Au and the dendrimer in enhancement of transgene silencing.

Publisher

Walter de Gruyter GmbH

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.sciendo.com/pdf/10.2478/acph-2019-0008

Reference30 articles.

1. 1. Z. Ziraksaz, A. Nomani, M. Soleimani, B. Bakhshandeh, E. Arefian, I. Haririan and M. Tabbakhian, Evaluation of cationic dendrimer and lipid as transfection reagents of short RNAs for stem cell modification, Int. J. Pharm.448 (2013) 231–238; https://doi.org/10.1016/j.ijpharm.2013.03.03510.1016/j.ijpharm.2013.03.035

2. 2. Y.-C. Tseng, S. Mozumdar and L. Huang, Lipid-based systemic delivery of siRNA, Adv. Drug Deliv. Rev.61 (2009) 721–731; https://doi.org/10.1016/j.addr.2009.03.00310.1016/j.addr.2009.03.003

3. 3. S. Dorasamy, N. Narainpersad, M. Singh and M. Ariatt, Novel targeted liposomes deliver sirna to hepatocellular carcinoma cells in vitro, Chem. Biol. Drug Des.80 (2012) 647–656; https://doi.org/10.1111/j.1747-0285.2012.01446.x10.1111/j.1747-0285.2012.01446.x

4. 4. M. Banan and N. Puri, The ins and outs of RNAi in mammalian cells, Curr. Pharm. Biotechnol.5 (2004) 441–450; https://doi.org/10.2174/138920104337664310.2174/1389201043376643

5. 5. D. J. Gary, N. Puri and Y.-Y. Won, Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery, J. Control. Rel.121 (2007) 64–73; https://doi:10.1016/j.jconrel.2007.05.02110.1016/j.jconrel.2007.05.021

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanotechnology-Driven Therapeutic Innovations in Neurodegenerative Disorders: A Focus on Alzheimer’s and Parkinson’s Disease;Future Pharmacology;2024-04-30

2. Target-Specific Delivery and Bioavailability of Pharmaceuticals via Janus and Dendrimer Particles;Pharmaceutics;2023-05-29

3. Dendrimer-Mediated Delivery of DNA and RNA Vaccines;Pharmaceutics;2023-03-30

4. Nanoconstructs for theranostic application in cancer: Challenges and strategies to enhance the delivery;Frontiers in Pharmacology;2023-03-15

5. A combinatorial delivery of survivin targeted siRNA using cancer selective nanoparticles for triple negative breast cancer therapy;Journal of Drug Delivery Science and Technology;2023-02